

Amendments to the Claims

Please add claims 46-49. Following this amendment claims 22, 23 and 35-49 will be pending, with claims 35-44 withdrawn.

Claims 1-21. (cancelled).

Claims 22. (Previously Presented): A method for enhancing the effectiveness of a nicotine replacement therapy consisting essentially of: administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of (a) nicotine and (b) one or more substances selected from the group consisting of (i) substances which inhibit CYP2A activity; (ii) substances which inhibit transcription, and/or translation of the gene encoding CYP2A; and (iii) substances which delete all or a portion of the gene encoding CYP2A; and optionally (c) one or more substances selected from the group consisting of substances which inhibit CYP2B6 activity, substances which inhibit transcription and/or translation of the gene encoding CYP2B6, or a combination thereof;

wherein (a), (b), and (c) if present, are administered contemporaneously.

Claim 23. (Currently Amended): A method according to claim 22 wherein said substance which inhibits CYP2A is methoxsalen, psoralen, tranlycypromine, pilocarpine, coumarin, chromone, esculetin, phenelzine, paroxetine, selegiline, ~~or~~, pargyline, or combinations thereof.

Claims 24-34 (Cancelled).

Claim 35. (Currently Amended): ~~The method according to claim 22, wherein the substances of group (c) are selected from/ phenylethyl amines, diphenylbarbiturates, diethyl substituted barbiturates, and hydantoins, and combinations thereof.~~

Claim 36. (Currently Amended): A method for enhancing the effectiveness of a nicotine replacement therapy comprising: administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and one or more substances

which inhibit CYP2A activity;

12 wherein the substance substances which inhibits CYP2A activity is one or more selected from methoxsalen, psoralen, tranlycypromine, coumarin, chromone, esculetin, phenelzine, paroxetine, selegiline and pargyline, *Hypericum* and extracts thereof, *Cichorium intybus* and extracts thereof, and *Bougainvillra spectabilis* and extracts thereof.

Claim 37. (Withdrawn): A method for enhancing the effectiveness of a nicotine replacement therapy comprising: administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and one or more substances which inhibit transcription, and/or translation of the gene encoding CYP2A.

Claim 38. (Withdrawn): A method for enhancing the effectiveness of a nicotine replacement therapy comprising: administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and one or more substances which delete all or a portion of the gene encoding CYP2A.

Claim 39. (Withdrawn): A method according to claims 36, wherein methoxsalen is administered in an amount from 0.1 mg to 50 mg.

Claim 40. (Withdrawn) A method according to claim 36, wherein coumarin is administered in an amount from 1 mg to 1000 mg.

Claim 41. (Withdrawn) A method according to claim 36, wherein tranlycypromine is administered in an amount from 0.1 mg to 80 mg.

Claim 42. (Withdrawn): A method for enhancing the effectiveness of a nicotine replacement therapy comprising administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and methoxsalen.

Claim 43. (Withdrawn): A method for enhancing the effectiveness of a nicotine replacement therapy comprising administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and coumarin.

Claim 44. (Withdrawn): A method for enhancing the effectiveness of a nicotine replacement therapy comprising administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and tranlycypromine.

Claim 45. (Previously Presented): A method for enhancing the effectiveness of a nicotine replacement therapy consisting essentially of: administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of (a) nicotine and (b) one or more substances selected from the group consisting of (i) substances which inhibit CYP2A activity; (ii) substances which inhibit transcription, and/or translation of the gene encoding CYP2A; and (iii) substances which delete all or a portion of the gene encoding CYP2A; wherein (a) and (b) are administered contemporaneously.

Claim 46 (New) A method according to claims 42, wherein methoxsalen is administered in an amount from 0.1 mg to 50 mg.

Claim 47 (New) A method for enhancing the effectiveness of a nicotine replacement therapy consisting of administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and methoxsalen.

Claim 48 (New) A method for enhancing the effectiveness of a nicotine replacement therapy comprising contemporaneously administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of (a) one or more substances which selectively inhibit CYP2A activity and (b) nicotine.

Claim 49 (New) The method of claim 48 wherein the substance which inhibits CYP2A activity is selected from methoxsalen, psoralen, tranlycypromine, coumarin, chromone, esculetin, phenelzine, paroxetine, selegiline and pargyline, *Hypericum* and extracts

thereof, *Cichorium intybus* and extracts thereof, and *Bougainvillra spectabilis* and extracts thereof.
